Addressing Clinical Challenges in T-Cell Lymphomas Through Biomarker-Driven Therapy

Addressing Clinical Challenges in T-Cell Lymphomas Through Biomarker-Driven Therapy

Friday, December 10, 2021 in Atlanta, GA
Live Meeting -- Marriott Marquis Atlanta, 3:00 PM ET
Marquis Ballroom BCD


Welcome, Introduction, and Baseline Assessment

  • Overview of Modern Molecular and Phenotypic Workup for T-Cell Lymphomas
    • Diagnostic workup and biomarker assessment
  • Planning Frontline Treatment for PTCL and CTCL Subtypes
    • Novel targeted agents and combination strategies
  • Improving Outcomes for Relapsed/Refractory PTCL and CTCL Subtypes
    • Novel targeted agents and combination strategies
  • Anaplastic Large Cell Lymphoma Treatment Algorithm and Ongoing Clinical Trials

Final Thoughts and Audience Question and Answer Session


Program Director
Steven M. Horwitz, MD

Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Memorial Hospital
Professor of Medicine, Weill Cornell Medical College
New York, New York

Francine Foss, MD

Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Barbara Pro, MD

Professor of Medicine
Division of Hematology/Oncology
Northwestern University
Chicago, Illinois

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers to optimally integrate new data in T-cell lymphomas into everyday clinical practice.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with T-cell lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the role of molecular and phenotypic biomarkers for individualizing treatment decisions in patients with TCL subtypes to improve accuracy of lymphoma subclassification
  • Plan treatment using single-agent or combination targeted therapy for patients with TCLs
  • Explore the latest clinical trial data for novel agents and emerging therapeutic strategies across different TCLs
  • Formulate methods for monitoring and managing adverse events associated with therapies for TCLs throughout multiple lines of treatment


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.